Media headlines about Coherus BioSciences (NASDAQ:CHRS) have been trending somewhat positive on Sunday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Coherus BioSciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.6316284844448 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

CHRS has been the topic of a number of recent analyst reports. Credit Suisse Group reiterated a “buy” rating and issued a $38.00 price objective on shares of Coherus BioSciences in a report on Friday, April 21st. BMO Capital Markets initiated coverage on Coherus BioSciences in a report on Friday, May 5th. They issued an “outperform” rating and a $54.00 price objective on the stock. Maxim Group set a $43.00 price objective on Coherus BioSciences and gave the company a “buy” rating in a report on Monday, May 15th. ValuEngine upgraded Coherus BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price objective on shares of Coherus BioSciences in a report on Tuesday, June 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $35.90.

Coherus BioSciences (NASDAQ:CHRS) traded up 1.08% on Friday, reaching $11.65. The company’s stock had a trading volume of 408,663 shares. Coherus BioSciences has a 52 week low of $10.80 and a 52 week high of $31.98. The firm has a 50 day moving average price of $13.61 and a 200 day moving average price of $19.60. The stock’s market capitalization is $598.18 million.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.21. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. The company had revenue of $1.40 million during the quarter. On average, equities analysts anticipate that Coherus BioSciences will post ($5.13) EPS for the current year.

In other news, insider Alan C. Herman sold 17,535 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the sale, the insider now directly owns 49,651 shares of the company’s stock, valued at approximately $745,758.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 32.88% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Coherus BioSciences (NASDAQ:CHRS) Earns Media Sentiment Rating of 0.17” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with's FREE daily email newsletter.